Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 135

1.

Stent migration requiring surgical removal: a serious adverse event after bariatric megastent placement.

Madruga Neto AC, Brunaldi VO, Okazaki O, Santo Filho MA, Miranda Neto AA, Anapaz VL, de Moura EGH.

Endoscopy. 2018 Dec;50(12):E344-E345. doi: 10.1055/a-0725-7718. Epub 2018 Oct 17.

PMID:
30332690
2.

Pacemaker malfunction after acute myocardial infarction in a patient with wrap-around left anterior descending artery supplying the right ventricular apex.

Umei TC, Awaya T, Okazaki O, Hara H, Hiroi Y.

J Cardiol Cases. 2018 Apr 4;18(1):9-12. doi: 10.1016/j.jccase.2018.03.001. eCollection 2018 Jul.

3.

Efficacy and Safety of Stents in the Treatment of Fistula After Bariatric Surgery: a Systematic Review and Meta-analysis.

Okazaki O, Bernardo WM, Brunaldi VO, Junior CCC, Minata MK, de Moura DTH, de Souza TF, Campos JM, Santo MA, de Moura EGH.

Obes Surg. 2018 Jun;28(6):1788-1796. doi: 10.1007/s11695-018-3236-6. Review.

PMID:
29654447
4.

Significance of 11C-PIB PET/CT in cardiac amyloidosis compared with 99mTc-aprotinin scintigraphy: A pilot study.

Minamimoto R, Awaya T, Iwama K, Hotta M, Nakajima K, Hirai R, Okazaki O, Hiroi Y.

J Nucl Cardiol. 2018 Mar 27. doi: 10.1007/s12350-018-1260-5. [Epub ahead of print]

PMID:
29589208
5.

Circulating odd-chain saturated fatty acids were associated with arteriosclerosis among patients with diabetes, dyslipidemia, or hypertension in Sri Lanka but not Japan.

Kurotani K, Karunapema P, Jayaratne K, Sato M, Hayashi T, Kajio H, Fukuda S, Hara H, Okazaki O, Jayatilleke AU, Nonaka D, Noda M, Mizoue T.

Nutr Res. 2018 Feb;50:82-93. doi: 10.1016/j.nutres.2017.12.004. Epub 2017 Dec 17.

6.

Endoscopic Treatment of Weight Regain Following Roux-en-Y Gastric Bypass: a Systematic Review and Meta-analysis.

Brunaldi VO, Jirapinyo P, de Moura DTH, Okazaki O, Bernardo WM, Galvão Neto M, Campos JM, Santo MA, de Moura EGH.

Obes Surg. 2018 Jan;28(1):266-276. doi: 10.1007/s11695-017-2986-x. Review.

PMID:
29082456
7.

Efficacy and Safety of an Orally Administered Selective Prostacyclin Receptor Agonist, Selexipag, in Japanese Patients With Pulmonary Arterial Hypertension.

Tanabe N, Ikeda S, Tahara N, Fukuda K, Hatano M, Ito H, Nakayama T, Anzai T, Hashimoto A, Inoue T, Kajinami K, Kihara Y, Kinoshita H, Kuwahara K, Murohara T, Okazaki O, Sakai S, Satoh T, Takeda Y, Takeishi Y, Taniguchi M, Watanabe H, Yamamoto T, Yamauchi-Takihara K, Yoshioka K, Sasayama S.

Circ J. 2017 Aug 25;81(9):1360-1367. doi: 10.1253/circj.CJ-16-1348. Epub 2017 Apr 18.

8.

Dose Timing of an Angiotensin II Receptor Blocker/Calcium Channel Blocker Combination in Hypertensive Patients With Paroxysmal Atrial Fibrillation.

Kario K, Hoshide S, Uchiyama K, Yoshida T, Okazaki O, Noshiro T, Aoki H, Mizuno H, Matsumoto Y.

J Clin Hypertens (Greenwich). 2016 Oct;18(10):1036-1044. doi: 10.1111/jch.12814. Epub 2016 Mar 16.

9.

Promising toxicological biomarkers for the diagnosis of liver injury types: Bile acid metabolic profiles and oxidative stress marker as screening tools in drug development.

Masubuchi N, Nishiya T, Imaoka M, Mizumaki K, Okazaki O.

Chem Biol Interact. 2016 Aug 5;255:74-82. doi: 10.1016/j.cbi.2015.09.012. Epub 2015 Sep 11.

PMID:
26365562
10.

Visual findings of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with cardiac sarcoidosis.

Ito K, Okazaki O, Morooka M, Kubota K, Minamimoto R, Hiroe M.

Intern Med. 2014;53(18):2041-9. Epub 2014 Sep 15.

11.

Long fasting is effective in inhibiting physiological myocardial 18F-FDG uptake and for evaluating active lesions of cardiac sarcoidosis.

Morooka M, Moroi M, Uno K, Ito K, Wu J, Nakagawa T, Kubota K, Minamimoto R, Miyata Y, Okasaki M, Okazaki O, Yamada Y, Yamaguchi T, Hiroe M.

EJNMMI Res. 2014 Jan 2;4(1):1. doi: 10.1186/2191-219X-4-1.

12.

Screening for gestational diabetes mellitus and its prevalence in Bangladesh.

Jesmin S, Akter S, Akashi H, Al-Mamun A, Rahman MA, Islam MM, Sohael F, Okazaki O, Moroi M, Kawano S, Mizutani T.

Diabetes Res Clin Pract. 2014 Jan;103(1):57-62. doi: 10.1016/j.diabres.2013.11.024. Epub 2013 Dec 7.

PMID:
24369985
13.

Re-evaluating the potentials and limitations of (99m)Tc-aprotinin scintigraphy for amyloid imaging.

Minamimoto R, Kubota K, Ishii K, Morooka M, Okasaki M, Miyata Y, Nakajima K, Sato T, Igari T, Hirai R, Okazaki O.

Am J Nucl Med Mol Imaging. 2013 Apr 9;3(3):261-71. Print 2013.

14.

Metabolic syndrome among pre- and post-menopausal rural women in Bangladesh: result from a population-based study.

Jesmin S, Islam AM, Akter S, Islam MM, Sultana SN, Yamaguchi N, Okazaki O, Moroi M, Hiroe M, Kimura S, Watanabe T, Saturo K, Mizutani T.

BMC Res Notes. 2013 Apr 18;6:157. doi: 10.1186/1756-0500-6-157.

15.

Incidental focal FDG uptake in heart is a lighthouse for considering cardiac screening.

Minamimoto R, Morooka M, Miyata Y, Ito K, Okasaki M, Hara H, Okazaki O, Moroi M, Kubota K.

Ann Nucl Med. 2013 Jul;27(6):572-80. doi: 10.1007/s12149-013-0721-9. Epub 2013 Apr 2.

PMID:
23546808
16.

A cross-sectional survey of blood pressure of a coastal city's resident victims of the 2011 Tohoku tsunami.

Murakami H, Akashi H, Noda S, Mizoue T, Okazaki O, Ouchi Y, Okaji Y, Kajiwara C, Miyoshi C.

Am J Hypertens. 2013 Jun;26(6):799-807. doi: 10.1093/ajh/hpt022. Epub 2013 Mar 2.

PMID:
23455946
17.

Complete atrioventricular block associated with not apical but midventricular ballooning.

Wakiya M, Hara H, Iwano M, Nakagawa T, Kayo T, Kamimura M, Ikeda N, Tamori Y, Yamamoto M, Ito S, Okazaki O, Moroi M.

J Cardiol Cases. 2013 Feb 6;7(4):e109-e113. doi: 10.1016/j.jccase.2012.12.003. eCollection 2013 Apr.

18.

Disruption of components of vascular endothelial growth factor angiogenic signalling system in metabolic syndrome. Findings from a study conducted in rural Bangladeshi women.

Jesmin S, Akter S, Rahman MM, Islam MM, Islam AM, Sultana SN, Mowa CN, Yamaguchi N, Okazaki O, Satoru K, Kimura S, Hiroe M, Mizutani T, Moroi M.

Thromb Haemost. 2013 Apr;109(4):696-705. doi: 10.1160/TH12-09-0654. Epub 2013 Jan 31.

PMID:
23364276
19.

Efficacy of heparin loading during an 18F-FDG PET/CT examination to search for cardiac sarcoidosis activity.

Ito K, Morooka M, Okazaki O, Minaminoto R, Kubota K, Hiroe M.

Clin Nucl Med. 2013 Feb;38(2):128-30. doi: 10.1097/RLU.0b013e318266cb25.

PMID:
23334129
20.

Association of age at menarche with metabolic syndrome and its components in rural Bangladeshi women.

Akter S, Jesmin S, Islam M, Sultana SN, Okazaki O, Hiroe M, Moroi M, Mizutani T.

Nutr Metab (Lond). 2012 Nov 9;9(1):99. doi: 10.1186/1743-7075-9-99.

21.

Amyloid imaging mismatch.

Minamimoto R, Ishii K, Kubota K, Morooka M, Okasaki M, Ito K, Mitsumoto T, Nakajima K, Sato T, Mochizuki M, Okazaki O.

Clin Nucl Med. 2012 Aug;37(8):807-9. doi: 10.1097/RLU.0b013e318251e1d3.

PMID:
22785519
22.

Novel comb-shaped PEG modification enhances the osteoclastic inhibitory effect and bone delivery of osteoprotegerin after intravenous administration in ovariectomized rats.

Miyaji Y, Kasuya Y, Furuta Y, Kurihara A, Takahashi M, Ogawara K, Izumi T, Okazaki O, Higaki K.

Pharm Res. 2012 Nov;29(11):3143-55. doi: 10.1007/s11095-012-0807-4. Epub 2012 Jun 23.

PMID:
22729371
23.

Glutathione S-transferase pi trapping method for generation and characterization of drug-protein adducts in human liver microsomes using liquid chromatography-tandem mass spectrometry.

Yukinaga H, Iwabuchi H, Okazaki O, Izumi T.

J Pharm Biomed Anal. 2012 Aug-Sep;67-68:186-92. doi: 10.1016/j.jpba.2012.04.035. Epub 2012 May 2.

PMID:
22608530
24.

Computer simulation of clinical electrophysiological study.

Zhu X, Wei D, Okazaki O.

Pacing Clin Electrophysiol. 2012 Jun;35(6):718-29. doi: 10.1111/j.1540-8159.2012.03379.x. Epub 2012 May 3.

PMID:
22554232
25.

In vitro evaluation of the potential for drug-induced toxicity based on (35)S-labeled glutathione adduct formation and daily dose.

Miyaji Y, Makino C, Kurihara A, Suzuki W, Okazaki O.

Bioanalysis. 2012 Feb;4(3):263-9. doi: 10.4155/bio.11.316.

PMID:
22303830
26.

Prevalence of metabolic syndrome among rural Bangladeshi women.

Jesmin S, Mia S, Islam AM, Islam R, Sultana SN, Zaedi S, Yamaguchi N, Okazaki O, Moroi M, Kimura S, Hiroe M.

Diabetes Res Clin Pract. 2012 Jan;95(1):e7-9. doi: 10.1016/j.diabres.2011.09.025. Epub 2011 Oct 19.

PMID:
22015482
27.

Inhibition mechanism of carbapenem antibiotics on acylpeptide hydrolase, a key enzyme in the interaction with valproic acid.

Suzuki E, Nakai D, Yamamura N, Kobayashi N, Okazaki O, Izumi T.

Xenobiotica. 2011 Nov;41(11):958-63. doi: 10.3109/00498254.2011.596582. Epub 2011 Jul 20.

PMID:
21770850
28.

Distribution of KAI-9803, a novel δ-protein kinase C inhibitor, after intravenous administration to rats.

Miyaji Y, Walter S, Chen L, Kurihara A, Ishizuka T, Saito M, Kawai K, Okazaki O.

Drug Metab Dispos. 2011 Oct;39(10):1946-53. doi: 10.1124/dmd.111.040725. Epub 2011 Jun 28.

PMID:
21712433
29.

In vitro metabolism of rivoglitazone, a novel peroxisome proliferator-activated receptor γ agonist, in rat, monkey, and human liver microsomes and freshly isolated hepatocytes.

Uchiyama M, Koda H, Fischer T, Mueller J, Yamamura N, Oguchi M, Iwabuchi H, Okazaki O, Izumi T.

Drug Metab Dispos. 2011 Jul;39(7):1311-9. doi: 10.1124/dmd.111.038729. Epub 2011 Apr 21.

PMID:
21511943
30.

Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.

Nakayama S, Takakusa H, Watanabe A, Miyaji Y, Suzuki W, Sugiyama D, Shiosakai K, Honda K, Okudaira N, Izumi T, Okazaki O.

Drug Metab Dispos. 2011 Jul;39(7):1247-54. doi: 10.1124/dmd.111.039180. Epub 2011 Apr 5.

PMID:
21467212
31.

Value of FDG-PET/CT using unfractionated heparin for managing primary cardiac lymphoma and several key findings.

Minamimoto R, Morooka M, Kubota K, Ito K, Masuda-Miyata Y, Mitsumoto T, Hirai R, Okazaki O, Hiroe M.

J Nucl Cardiol. 2011 May;18(3):516-20. doi: 10.1007/s12350-011-9358-z. No abstract available.

PMID:
21394554
32.

Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.

Deguchi T, Watanabe N, Kurihara A, Igeta K, Ikenaga H, Fusegawa K, Suzuki N, Murata S, Hirouchi M, Furuta Y, Iwasaki M, Okazaki O, Izumi T.

Drug Metab Dispos. 2011 May;39(5):820-9. doi: 10.1124/dmd.110.037457. Epub 2011 Jan 31.

PMID:
21282406
33.

Pharmacokinetics, metabolism, and disposition of rivoglitazone, a novel peroxisome proliferator-activated receptor γ agonist, in rats and monkeys.

Uchiyama M, Iwabuchi H, Tsuruta F, Abe K, Takahashi M, Koda H, Oguchi M, Okazaki O, Izumi T.

Drug Metab Dispos. 2011 Apr;39(4):653-66. doi: 10.1124/dmd.110.036194. Epub 2010 Dec 21.

PMID:
21177486
34.

Prediction of fluoroquinolone-induced elevation in serum creatinine levels: a case of drug-endogenous substance interaction involving the inhibition of renal secretion.

Imamura Y, Murayama N, Okudaira N, Kurihara A, Okazaki O, Izumi T, Inoue K, Yuasa H, Kusuhara H, Sugiyama Y.

Clin Pharmacol Ther. 2011 Jan;89(1):81-8. doi: 10.1038/clpt.2010.232. Epub 2010 Dec 1.

PMID:
21124314
35.

Derive right precordial leads at higher intercostal spaces from 12-lead system for diagnosis of Brugada syndrome.

Zhu X, Wei D, Okazaki O.

Conf Proc IEEE Eng Med Biol Soc. 2010;2010:2581-4. doi: 10.1109/IEMBS.2010.5626662.

PMID:
21096175
36.

Ticlopidine-induced hepatotoxicity in a GSH-depleted rat model.

Shimizu S, Atsumi R, Nakazawa T, Izumi T, Sudo K, Okazaki O, Saji H.

Arch Toxicol. 2011 Apr;85(4):347-53. doi: 10.1007/s00204-010-0594-9. Epub 2010 Sep 25.

PMID:
20871981
37.

PEGylation of osteoprotegerin/osteoclastogenesis inhibitory factor (OPG/OCIF) results in decreased uptake into rats and human liver.

Saito-Yabe M, Kasuya Y, Yoshigae Y, Yamamura N, Suzuki Y, Fukuda N, Honma M, Yano K, Mochizuki S, Okada F, Okada A, Nagayama Y, Tsuda E, Fischer T, Höpner U, Zaja S, Mueller J, Okada J, Kurihara A, Ikeda T, Okazaki O.

J Pharm Pharmacol. 2010 Aug;62(8):985-94. doi: 10.1111/j.2042-7158.2010.01120.x.

PMID:
20663032
38.

Ethylene glycol monomethyl ether-induced toxicity is mediated through the inhibition of flavoprotein dehydrogenase enzyme family.

Takei M, Ando Y, Saitoh W, Tanimoto T, Kiyosawa N, Manabe S, Sanbuissho A, Okazaki O, Iwabuchi H, Yamoto T, Adam KP, Weiel JE, Ryals JA, Milburn MV, Guo L.

Toxicol Sci. 2010 Dec;118(2):643-52. doi: 10.1093/toxsci/kfq211. Epub 2010 Jul 8.

39.

Estimation of the interindividual variability of cytochrome 2D6 activity from urinary metabolic ratios in the literature.

Ito T, Kato M, Chiba K, Okazaki O, Sugiyama Y.

Drug Metab Pharmacokinet. 2010;25(3):243-53.

40.

Predictability of idiosyncratic drug toxicity risk for carboxylic acid-containing drugs based on the chemical stability of acyl glucuronide.

Sawamura R, Okudaira N, Watanabe K, Murai T, Kobayashi Y, Tachibana M, Ohnuki T, Masuda K, Honma H, Kurihara A, Okazaki O.

Drug Metab Dispos. 2010 Oct;38(10):1857-64. doi: 10.1124/dmd.110.034173. Epub 2010 Jul 6. Erratum in: Drug Metab Dispos. 2010 Dec;38(12):2347.

PMID:
20606003
41.

Identification of valproic acid glucuronide hydrolase as a key enzyme for the interaction of valproic acid with carbapenem antibiotics.

Suzuki E, Yamamura N, Ogura Y, Nakai D, Kubota K, Kobayashi N, Miura S, Okazaki O.

Drug Metab Dispos. 2010 Sep;38(9):1538-44. doi: 10.1124/dmd.110.032938. Epub 2010 Jun 15.

PMID:
20551238
43.

Evaluation of pharmacogenetic algorithm for warfarin dose requirements in Japanese patients.

Takeuchi F, Kashida M, Okazaki O, Tanaka Y, Fukuda S, Kashima T, Hosaka S, Hiroe M, Kimura S, Kato N.

Circ J. 2010 May;74(5):977-82. Epub 2010 Mar 26.

44.

Biotransformation of prasugrel, a novel thienopyridine antiplatelet agent, to the pharmacologically active metabolite.

Hagihara K, Kazui M, Kurihara A, Iwabuchi H, Ishikawa M, Kobayashi H, Tanaka N, Okazaki O, Farid NA, Ikeda T.

Drug Metab Dispos. 2010 Jun;38(6):898-904. doi: 10.1124/dmd.110.032086. Epub 2010 Mar 12.

PMID:
20228231
45.

Human carboxymethylenebutenolidase as a bioactivating hydrolase of olmesartan medoxomil in liver and intestine.

Ishizuka T, Fujimori I, Kato M, Noji-Sakikawa C, Saito M, Yoshigae Y, Kubota K, Kurihara A, Izumi T, Ikeda T, Okazaki O.

J Biol Chem. 2010 Apr 16;285(16):11892-902. doi: 10.1074/jbc.M109.072629. Epub 2010 Feb 19.

46.

Pharmacokinetics and disposition of CS-8958, a long-acting prodrug of the novel neuraminidase inhibitor laninamivir in rats.

Koyama K, Takahashi M, Nakai N, Takakusa H, Murai T, Hoshi M, Yamamura N, Kobayashi N, Okazaki O.

Xenobiotica. 2010 Mar;40(3):207-16. doi: 10.3109/00498250903447691.

PMID:
20146556
47.

Interaction of angiotensin II type 1 receptor blockers with P-gp substrates in Caco-2 cells and hMDR1-expressing membranes.

Kamiyama E, Nakai D, Mikkaichi T, Okudaira N, Okazaki O.

Life Sci. 2010 Jan 2;86(1-2):52-8. doi: 10.1016/j.lfs.2009.11.006. Epub 2009 Nov 13.

PMID:
19914261
48.

Effects of organic solvents on the time-dependent inhibition of CYP3A4 by diazepam.

Nishiya Y, Nakamura K, Okudaira N, Abe K, Kobayashi N, Okazaki O.

Xenobiotica. 2010 Jan;40(1):1-8. doi: 10.3109/00498250903337392.

PMID:
19905875
49.

Comparison of mechanism-based inhibition of human cytochrome P450 2C19 by ticlopidine, clopidogrel, and prasugrel.

Nishiya Y, Hagihara K, Kurihara A, Okudaira N, Farid NA, Okazaki O, Ikeda T.

Xenobiotica. 2009 Nov;39(11):836-43. doi: 10.3109/00498250903191427.

PMID:
19845434
50.

Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite.

Kazui M, Nishiya Y, Ishizuka T, Hagihara K, Farid NA, Okazaki O, Ikeda T, Kurihara A.

Drug Metab Dispos. 2010 Jan;38(1):92-9. doi: 10.1124/dmd.109.029132.

PMID:
19812348

Supplemental Content

Loading ...
Support Center